Millions of women diagnosed with polyendocrine metabolic ovarian syndrome (PMOS) may benefit from annual NHS check-ups and earlier identification based on new preliminary recommendations from the healthcare regulator.
According to the guidance issued by NICE, women living with PMOS, previously known as polycystic ovary syndrome (PCOS), are advised to undergo yearly evaluations to monitor the chronic hormone disorder associated with diabetes, heart problems, fertility issues, and mental health challenges. Despite affecting approximately one in eight women, medical professionals often overlook this condition, leading to prolonged struggles in managing symptoms.
Sharon Mansfield, part of the committee involved in formulating NICE’s draft guidance, shared her experience of being disregarded by doctors for ten years regarding her irregular periods, weight concerns, and mental health issues before finally receiving a diagnosis in her mid-30s. She expressed hope that the new recommendations will prompt earlier and more serious attention for the estimated 3-4 million UK women with PMOS.
The draft guideline includes detailed information on recognizing and diagnosing the condition to facilitate timely identification. Additionally, NICE highlighted the importance of healthcare providers acknowledging the potentially higher prevalence of PMOS among Black, Asian, and mixed-ethnicity women when evaluating symptoms.
Upon diagnosis, women would be offered an annual health assessment to track symptoms and detect early signs of conditions such as diabetes, enabling healthcare professionals to suggest lifestyle adjustments before complications arise. In addition to the existing NHS support, women planning pregnancies should also receive guidance on managing PMOS, including information on fertility treatments, including IVF where suitable.
The transition from polycystic ovary syndrome (PCOS) to PMOS was part of a global initiative by experts to address misunderstandings surrounding the condition and recognize its broad “metabolic implications” affecting overall health, not just the ovaries.
Marie Anne Ledingham, a consultant clinical advisor specializing in women’s and reproductive health at NICE, emphasized that the annual review marks a significant advancement in continuous care provision for women. Ledingham stressed the importance of addressing PMOS, a prevalent yet often neglected condition with substantial implications for health and well-being.
NICE is seeking feedback on the preliminary guideline from doctors, patients, and the public during the consultation period running from July 1 to August 11. The final guideline on PMOS is slated for publication in December 2026.